You are here

P&T News

March 23

How will it impact the competition?
Option approved to treat all forms of diabetic retinopathy in people with or without diabetic macular edema
Advocacy groups, former FDA commissioners express concern
First FDA-approved regimen in frontline stage III or IV classical Hodgkin’s lymphoma in more than 40 years
Initial 2007 approval allowed use of the drug only in adult patients

March 20

Treatment tested after bunionectomy and hernia repair surgery
Study is ongoing to determine overall survival in patients with certain lung cancer
Shingrix now available at more than 9,800 CVS pharmacies around the U.S.
New collaborative opportunities underway to create change
Number of Alzheimer’s deaths increased 123% while deaths from other major causes decreased over 15-year period

March 15

More drugs or more costly drugs are being prescribed, industry trade group says
Risk approaches 13% for women who fall ill early in pregnancy
Alexion announces positive top-line results for ALXN1210 in PNH
Increased risk of high-frequency hearing loss pegged at 60%
Janssen drug targets metastatic urothelial cancer, marked by poor outcomes

March 13

Researchers say this real-world study in Canada should also apply to the U.S.
The results from a seven-year study were “entirely unexpected”
Generic competition pushed back to at least mid-2018
Report identifies critical need to minimize financial toxicity and increase access
Nearly 64% achieved healthy levels after barbers promoted follow-up

Pages